GLOW is a community and research-market name commonly used for a three-component peptide blend containing GHK-Cu, BPC-157, and TB-500. A commonly documented formulation is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500, although GLOW is not a universally standardized clinical formulation.
The important distinction is between evidence for the individual components and evidence for the combination itself. Research involving an individual peptide does not establish efficacy, safety, compatibility, or synergy for the complete GLOW combination.
GLOW is best described as a named research-market/community blend, not as a standardized pharmaceutical formulation.
GLOW is a name used for a three-peptide combination consisting of GHK-Cu, BPC-157, and TB-500. Current research-market sources commonly describe a 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500 formulation, but the name itself is not a scientifically or clinically standardized formulation.
The term is therefore best categorized as community and commercial/research-market nomenclature. It should not be treated as the name of an FDA-approved drug, established clinical protocol, or universally defined pharmaceutical composition.
A product can have a defined formulation from a particular supplier without the name itself being a standardized clinical formulation. Always verify the actual mass of each component from the product documentation or lot-specific information.
The commonly documented GLOW formulation contains three distinct peptide components. Their masses must remain separate when calculating concentration.
GHK-Cu is the copper-associated form of the tripeptide glycyl-histidyl-lysine. It has been investigated particularly in skin and tissue-remodeling contexts.
BPC-157 is a synthetic pentadecapeptide investigated extensively in preclinical models. Human research remains limited and has not established a validated therapeutic formulation or general clinical protocol.
TB-500 is commonly described in the research market as a thymosin-β4-related fragment. Its literature should not automatically be treated as equivalent to clinical evidence for the exact TB-500 material in a commercial blend.
GLOW is not the formal scientific name of a naturally occurring molecule.
There is no universally recognized clinical formulation called GLOW.
GLOW is commonly used as shorthand for the GHK-Cu + BPC-157 + TB-500 combination.
The commonly documented formulation analyzed on this page is 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500, producing 70 mg of total peptide material before considering formulation-specific excipients or other components.
| Formulation | GHK-Cu | BPC-157 | TB-500 | Total | Status |
|---|---|---|---|---|---|
| Commonly documented GLOW | 50 mg | 10 mg | 10 mg | 70 mg | Frequently documented |
| Other vendor formulations | May differ. Verify the actual mass of each component. | Not standardized | |||
The formulation shown above should therefore be treated as a reference formulation rather than a universal definition of every product marketed as GLOW.
Human research exists for topical copper tripeptide formulations, including research following CO₂ laser resurfacing. Such studies do not establish a general clinical benefit for the GLOW combination.
BPC-157 has extensive preclinical literature, while human evidence remains limited. Important gaps remain around pharmacokinetics, validated formulations and controlled clinical development.
Thymosin β4 itself has been studied in humans, but findings from thymosin β4 research should not automatically be equated with clinical evidence for a specific TB-500 fragment formulation.
No established controlled human clinical evidence has been identified evaluating GHK-Cu + BPC-157 + TB-500 together as the complete GLOW blend.
No established controlled human clinical evidence was identified evaluating the complete GHK-Cu + BPC-157 + TB-500 combination as the named GLOW formulation.
This distinction is fundamental. Studies involving GHK-Cu, BPC-157, or thymosin β4-related research do not automatically constitute studies of GLOW.
Individual-component evidence can support scientific hypotheses, but it does not establish that the complete combination produces additive or synergistic effects in humans.
For a multi-component vial, the correct mathematical approach is to calculate the concentration of each component independently. All three components share the same final liquid volume, but each component has its own mass.
Component concentration (mg/mL)
= component mass (mg) ÷ final liquid volume (mL)
This page provides concentration mathematics only. It does not
establish a dose, administration volume, route, frequency, or
human-use protocol.
Using the example formulation of 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500, every value below is independently calculated as component mass divided by the selected final liquid volume.
| Component | 1 mL | 2 mL | 3 mL | 5 mL | 10 mL |
|---|---|---|---|---|---|
| GHK-Cu — 50 mg | 50 mg/mL | 25 mg/mL | 16.67 mg/mL | 10 mg/mL | 5 mg/mL |
| BPC-157 — 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL | 1 mg/mL |
| TB-500 — 10 mg | 10 mg/mL | 5 mg/mL | 3.33 mg/mL | 2 mg/mL | 1 mg/mL |
GHK-Cu begins with five times the mass of either BPC-157 or TB-500. Therefore, at every identical liquid volume, its concentration is five times higher.
For example, at 5 mL: 50 mg ÷ 5 mL = 10 mg/mL GHK-Cu, while 10 mg ÷ 5 mL = 2 mg/mL BPC-157 and 10 mg ÷ 5 mL = 2 mg/mL TB-500.
GHK-Cu: 50 mg ÷ 1 mL = 50 mg/mL
BPC-157: 10 mg ÷ 1 mL = 10 mg/mL
TB-500: 10 mg ÷ 1 mL = 10 mg/mL
GHK-Cu: 50 mg ÷ 3 mL = 16.67 mg/mL
BPC-157: 10 mg ÷ 3 mL = 3.33 mg/mL
TB-500: 10 mg ÷ 3 mL = 3.33 mg/mL
GHK-Cu: 50 mg ÷ 5 mL = 10 mg/mL
BPC-157: 10 mg ÷ 5 mL = 2 mg/mL
TB-500: 10 mg ÷ 5 mL = 2 mg/mL
Do NOT calculate:
70 mg ÷ 5 mL = 14 mg/mL
14 mg/mL represents total peptide mass per mL under this simplified
mass model. It is NOT the individual concentration of GHK-Cu,
BPC-157, or TB-500.
Use the BacScience Universal BAC Water Calculator for single-compound concentration mathematics. For multi-component blends such as GLOW, calculate each component separately.
The rationale behind GLOW is generally associated with combining compounds that have been investigated in different areas of regenerative, tissue-related, cellular, or skin research.
These overlapping research themes help explain why the combination appears in research-market discussions. They do not establish that the combination produces additive or synergistic effects in humans.
Commonly described as GHK-Cu + BPC-157 + TB-500 .
A community nickname commonly associated with BPC-157 + TB-500 . It is not a standardized scientific formulation.
Often described as GLOW plus KPV . Exact commercial formulations should be verified rather than assumed to be universal.
The name is used across community and commercial sources. Formulation, component identity and quantities should be verified from the actual product documentation.
Research on one peptide cannot be used as evidence that the complete GLOW combination works.
Animal, cellular and mechanistic findings may help generate hypotheses but do not establish human clinical effectiveness.
Different peptide identities, purity profiles, analytical methods, manufacturing conditions and formulation components can make two similarly named products scientifically non-equivalent.
GLOW should not be presented as an approved medicine or clinically validated treatment. Regulatory considerations concerning individual substances are separate from the commercial/community name GLOW.
Regulatory status can change. Researchers should consult current regulator information and applicable institutional requirements rather than relying solely on commercial product labels or community terminology.
This page intentionally does not provide a human dosing protocol, administration instructions, injection volumes, treatment schedule, or recommendation to use the combination.
GLOW is commonly used as a name for a three-component combination of GHK-Cu, BPC-157 and TB-500. It is a community and research-market name rather than a universally standardized clinical formulation.
The commonly documented formulation contains GHK-Cu, BPC-157 and TB-500. A frequently documented mass split is 50 mg GHK-Cu, 10 mg BPC-157 and 10 mg TB-500.
No. The 50/10/10 mg formulation is commonly documented, but the name GLOW does not by itself guarantee a particular formulation. Verify the actual component quantities.
No established controlled human clinical evidence was identified for the complete GHK-Cu + BPC-157 + TB-500 combination. Evidence for individual components should not be presented as evidence for GLOW itself.
Calculate every component separately: component mass in mg divided by final liquid volume in mL.
No. Under the mathematical concentration model, the mass of each peptide remains fixed while its concentration per milliliter decreases as final volume increases.
No. Total peptide mass is not the individual concentration of each component. Each peptide must be calculated independently.
Not usually. Wolverine is commonly used for the BPC-157 + TB-500 pairing, while GLOW generally adds GHK-Cu.
KLOW is commonly described as GLOW plus KPV. However, names in this research-market space are not guaranteed to represent standardized pharmaceutical formulations.
For the example 50/10/10 mg formulation and a 5 mL final volume, the mathematical concentrations are 10 mg/mL GHK-Cu, 2 mg/mL BPC-157 and 2 mg/mL TB-500.
For another peptide or formulation, use the BacScience concentration calculator as a starting point for the mathematical calculation.
Last reviewed:
September 11, 2026
Research reference only. This page does not provide medical advice,
dosing instructions, administration instructions, or a validated
human-use protocol.